Researchers at City of Hope have developed a tool that could predict if older adults with early-stage breast cancer will develop a severe or deadly reaction to chemotherapy.   This...

Multiple myeloma patient Simon Bray Simon Bray grew up around horses and horse racing. As a boy in Hertford, England, he eagerly embraced the "sport of kings" as a kind...

A Phase 2 trial led by City of Hope suggests that adding the novel ataxia telangiectasia and Rad3-related (ATR) inhibitor drug berzosertib to standard-of-care chemotherapy for patients with metastatic urothelial...

The remarkable results of a new City of Hope study show that the natural botanical Andrographis paniculata, when given in conjunction with chemotherapy, may be a major breakthrough in...

CONTACT Zen Vuong 626-409-9367 zvuong@coh.org   The first-of-its-kind clinical trial suggests that implementing geriatric assessment-driven interventions could reduce significant chemotherapy-related toxicity for older adults while maintaining their ability to survive...

Chemotherapy and immunotherapy have proven to be powerful treatments for many types of cancer. Clinical developments and FDA approvals have made immunotherapeutic options increasingly available over the last decade, while...

Phase I trial of ipatasertib in combination with chemo- and immunotherapy options   Although metastatic triple-negative breast cancer (TNBC) makes up a minority of breast cancer cases (15-20%), it is...

CONTACT Zen Vuong 626-409-9367 zvuong@coh.org A therapy that combines a drug that disrupts DNA repair with chemotherapy cisplatin and gemcitabine does not prolong progression-free survival for patients with urothelial cancer...

CONTACTZen Vuong626-409-9367zvuong@coh.org This easy-to-use risk assessment tool provides oncologists and patients with an individualized report on the likelihood of severe chemotherapy side effects for elderly patients...